By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



330 Collins Street
Level 11
Melbourne  Victoria  3000  Australia
Phone: 61-3-9660-4900 Fax: 61-3-9660-4999


Company News
Clinuvel Release: NICE’s Technical Team Invited Stakeholders With An Interest In The Treatment Of erythropoietic protoporphyria (EPP) 3/24/2016 8:16:32 AM
Europe Approves Clinuvel's Novel Australian Drug Developed For Rare Sun Disease 10/24/2014 9:29:42 AM
Clinuvel Snags A $95 Million Takeover Bid From New York-Based Retrophin, Inc. (RTRX) 7/28/2014 6:04:02 AM
Clinuvel Commences US Phase III Trial of SCENESSE® in Rare Light and UV Disorder 5/22/2012 12:09:46 PM
Swiss Insurers Agree to Reimburse Clinuvel's SCENESSE® for Rare Disease 4/26/2012 11:41:55 AM
Clinuvel Files European Marketing Authorisation Application for SCENESSE® (afamelanotide) 2/6/2012 6:14:37 AM
Clinuvel Announces Positive Results From Pivotal European Phase III Study: Endpoints Demonstrate Clinically Relevant Treatment Effect of Afamelanotide 12/19/2011 3:03:58 PM
Clinuvel Announces Positive Results of First Phase II US Study of SCENESSE® in Orphan Disease Erythropoietic Protoporphyria (EPP) 11/3/2011 7:33:15 AM
EMA Acknowledges Clinuvel’s Novel Drug Filing in Europe in 2011 5/12/2011 9:38:35 AM
Clinuvel Release: FDA Allows World First Vitiligo Drug Trial 3/2/2011 2:53:28 PM